Kjelsåsveien 168 B
154 articles with Nordic Nanovector
Nordic Nanovector ASA announces its second quarter and first half 2018 results today. A presentation by the company's senior management team will take place today in Oslo at 08:30 CEST, see details below.
Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2018 Results Presentation and Webcast
Nordic Nanovector ASA announces its second quarter and first half 2018 results on Wednesday, 22 August 2018.
Reference is made to the stock exchange notice published by Nordic Nanovector ASA on 3 July 2018 where the Company announced that the board of directors of the Company had resolved to increase the Company's share capital in connection with the exercise of RSUs.
Nordic Nanovector ASA: Increase of Share Capital/Mandatory Notification of Trade and Issuance of PSUs
Three of the board members of Nordic Nanovector ASA, Gisela Schwab, Joanna Horobin and Jean-Pierre Bizzari, have resolved to settle a total number of 6,035 RSUs that were issued to them in June 2017
Mr. Bravo brings more than 25 years' experience in the biopharmaceutical industry and a strong track record in leading and growing international biotech and pharmaceutical organisations.
Nordic Nanovector Announces Archer-1 Trial of Betalutin® plus Rituximab in 2L Follicular Lymphoma Approved to Start in Norway
Nordic Nanovector ASA has received approval from the Regional Committees for Medical and Health Research Ethics (REK) in Norway with regard to the Clinical Trial Application (CTA) for the Archer-1 Phase 1b trial with Betalutin® (177Lu-satetraxetan-lilotomab) in combination with rituximab in second-line follicular lymphoma patients (2L FL).
Nordic Nanovector Announces Betalutin® has been Granted Fast Track Designation in the US for Follicular Lymphoma
Treatment of patients with relapsed or refractory follicular lymphoma (FL) after at least 2 prior systemic therapies.
Nordic Nanovector to Present Preclinical Data Demonstrating Betalutin® Reverses Resistance to Anti-CD20 Treatment in NHL Cells
Poster to be presented at Inaugural AACR International Meeting: Advances in Malignant Lymphoma
Shareholders approved the issuance of restricted stock units ("RSUs") to board members who elect to receive all or parts of their remuneration in the form of RSUs.
Nordic Nanovector Strengthens Management Team With Appointment of Maureen Deehan, PhD, as Head of Corporate Development and Strategy
Nordic Nanovector ASA (OSE: NANO) announces that Maureen Deehan, PhD, has been appointed as Head of Corporate Development and Strategy.
Nordic Nanovector to Present Pre-clinical Study of Betalutin® Effect on NHL Cells at European Hematology Association Meeting
Nordic Nanovector ASA announces that it will present a poster describing a preclinical analysis of genetic factors that correlate with the responsiveness of non-Hodgkin's lymphoma (NHL) cell lines to Betalutin® (177Lu-lilotomab satetraxetan) at the 23rd annual meeting of the European Hematology Association (EHA) (Stockholm, Sweden, 14-17 June).
The Annual General Meeting of Nordic Nanovector ASA was held 30 May in Oslo, Norway.
Nordic Nanovector ASA (OSE: NANO) today announces that Rainer Boehm, MD was elected as a member of its Board of Directors at the company's Annual General Meeting on 30 May 2018.
Nordic Nanovector ASA (OSE: NANO) announces its results for the first quarter 2018.
Nordic Nanovector ASA (OSE: NANO) announces that its pivotal PARADIGME Phase 2b trial with Betalutin® (177Lu-satetraxetan-lilotomab) in third-line (3L) follicular lymphoma (FL) patients has been approved by the Regional Committees for Medical and Health Research Ethics (REK) in Norway.
Nordic Nanovector ASA announces that in accordance with its new corporate disclosure policies, the company will introduce a two-week quiet period ahead of its full year and quarterly results announcements.
The Board of Directors of Nordic Nanovector ASA (OSE: NANO) has approved the company's Annual Report for 2017 including the complete 2017 Annual Accounts with notes. The report is attached to this announcement and available on Nordic Nanovector ASA's website in the section Investor Relations/Reports and presentations/Annual Reports.
Nordic Nanovector ASA (OSE: NANO) announces that it has appointed Tone Kvåle to the position of Interim Chief Executive Officer (CEO) in addition to her current role as Chief Financial Officer
Nordic Nanovector to Present Preclinical Data Highlighting the Anti-tumor Effect of Humalutin® in Three Lymphoma Models at AACR 2018
Nordic Nanovector ASA announces that it will present a poster reporting the anti-tumour effect of Humalutin® (177Lu-conjugated humanized anti-CD37 antibody, 177Lu-NNV003) in preclinical models of non-Hodgkin's lymphoma at the AACR Annual Meeting 2018.
Nordic Nanovector to Present at the China Healthcare Investing and Partnering Symposium in China and Stifel Nordic Healthcare Seminar in London
Nordic Nanovector ASA announces that the company will be presenting at two upcoming investor conferences.